At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
Cabazitaxeldrug
Likely dose
Cabazitaxel 25mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis
University Hospitals Bristol and Weston NHS Foundation Trust·interventional·Posted Apr 14, 2017·Updated Nov 18, 2022
In Brief
A Phase 2 clinical trial evaluating Cabazitaxel for Penile Neoplasm. Completed, enrolled 17 participants across 2 sites.
Detailed Summary
An evaluation of the activity of cabazitaxel chemotherapy in relapsed cancer of the penis. Safety and tolerability will be monitored and survival will be assessed. It is hypothesised that cabazitaxel is useful in increasing progression free survival in relapsed penile cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPenile Neoplasm
CountriesUnited Kingdom
CollaboratorsSanofi
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartDec 2014
Primary CompletionNov 2016
First PostedApr 2017
TodayJul 2026
First PostedApr 14, 2017
Enrollment StartDec 5, 2014
Primary CompletionNov 16, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.2 years ago
Interventions
Cabazitaxeldrug
Six cycles of chemotherapy comprising: Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days.